STOCK TITAN

Takeda Pharmaceutical Company (TAK) Stock News, Oct-Dec 2022

TAK NYSE

Takeda Pharmaceutical Company Limited reports news as a Japan-based, R&D-driven biopharmaceutical company whose American depositary shares trade under TAK. Its updates center on medicines and pipeline programs in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines, including ENTYVIO, GAMMAGARD LIQUID ERC, HYQVIA, TAK-881, zasocitinib, rusfertide and oveporexton.

Recurring developments include pivotal clinical trial data, U.S. FDA regulatory actions involving new drug applications, prescription product availability, collaboration updates, and financial reports. Takeda also reports on launch preparation, generic competition affecting established products, operating-cost discipline, foreign-exchange effects, corporate transformation initiatives and governance matters tied to its global pharmaceutical business.

Rhea-AI Summary

Nimbus Therapeutics has entered into a definitive agreement for Takeda to acquire its subsidiary, Nimbus Lakshmi, Inc., along with the TYK2 inhibitor NDI-034858. The deal includes $4 billion upfront and up to $2 billion in milestone payments. NDI-034858 is being developed for autoimmune diseases, showing promising Phase 2b results in psoriasis. The acquisition is set to close in the first half of 2023, pending antitrust reviews.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
-
Rhea-AI Summary

Takeda will present 15 company-sponsored and nine collaborative abstracts at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022, in New Orleans. Highlighted presentations include updates from the Phase 3 OPTIC trial of ICLUSIG (ponatinib) and a first-in-human study of Modakafusp Alfa (TAK-573). The research aims to enhance outcomes in patients with hematologic diseases, emphasizing novel treatment mechanisms and the importance of addressing unmet needs in this field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences
-
Rhea-AI Summary

The European Commission has approved QDENGA (TAK-003), a dengue vaccine for individuals aged four years and older. This makes QDENGA the only dengue vaccine approved in the EU for use, regardless of prior dengue exposure.

Approval is based on extensive clinical studies involving over 28,000 participants, showing 80.2% efficacy in preventing symptomatic dengue and 90.4% in preventing hospitalizations at 18 months. The vaccine is crucial for reducing dengue incidence, which has significantly risen globally. No changes are expected in Takeda's fiscal outlook for FY 2022 due to this approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
Rhea-AI Summary

Takeda has announced that the FDA has accepted the Biologics License Application (BLA) for TAK-003, its investigational dengue vaccine. The vaccine is aimed at preventing dengue disease caused by any virus serotype in individuals aged 4 to 60. With increasing dengue incidence and 888 infections reported in the U.S. this year, 96% of which were travel-related, the vaccine could become a crucial preventive option. The BLA is supported by a pivotal Phase 3 trial showing 80.2% efficacy at 12 months. Approval in Indonesia has been achieved, with ongoing regulatory reviews in Europe and other regions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none
-
Rhea-AI Summary

Takeda announced the successful results of the Phase 3 PhALLCON trial, which compared ICLUSIG® (ponatinib) with imatinib in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The trial met its primary endpoint, demonstrating superior rates of minimal residual disease (MRD)-negative complete remission for ICLUSIG. Given the urgency for effective therapies in this patient population, these findings highlight ICLUSIG’s potential in addressing treatment challenges associated with Ph+ ALL.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
-
Rhea-AI Summary

LIVTENCITY is now the first and only treatment for cytomegalovirus (CMV) infection approved by the European Commission (EC) for patients with post-transplant infections. CMV is a prevalent issue post-transplant, affecting 16-56% of solid organ transplant patients. The approval is based on the successful results of the Phase 3 SOLSTICE trial. LIVTENCITY targets the UL97 protein kinase, offering a novel option where previous therapies failed, enabling healthcare providers across the EU and EEA to manage refractory CMV cases effectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
Rhea-AI Summary

Takeda reported strong financial results for the first half of fiscal year 2022, with core revenue growth of 5.5% at constant exchange rates (CER) and reported revenue growth of 10.1%. Core operating profit grew 14.5% at CER, achieving a core operating profit margin of 31.7%. The company upgraded its peak sales outlook for ENTYVIO® to $7.5-9.0 billion and improved net debt to adjusted EBITDA to 2.6x. Takeda also reaffirmed its full-year guidance, reflecting strong performance in key business areas and ongoing product approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
Rhea-AI Summary

Takeda has entered into a collaboration with Zedira and Dr. Falk Pharma to exclusively develop and commercialize TAK-227 (ZED1227) for celiac disease in the U.S. and other regions outside of Europe, Canada, Australia, and China. This investigational oral therapy aims to inhibit the immune response to gluten, addressing a significant unmet need in celiac disease treatment. The agreement adds a promising candidate to Takeda's pipeline, which already includes two other investigational therapies for celiac disease, both recently entering Phase 2 trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
Rhea-AI Summary

Takeda announced a positive opinion from the European Medicines Agency's CHMP for its dengue vaccine candidate, TAK-003. This recommendation supports the vaccine's use in individuals aged four and older across Europe and dengue-endemic countries. The decision is based on over 4.5 years of safety and efficacy data from a pivotal Phase 3 trial involving more than 20,000 participants. Marketing authorization in Europe is anticipated soon, with further regulatory reviews expected in Latin America and Asia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none
Rhea-AI Summary

Takeda has announced that the FDA has accepted a supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO (lanadelumab-flyo) to prevent hereditary angioedema (HAE) attacks in pediatric patients aged 2 to 12 years old.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.10%
Tags
none

FAQ

What is the current stock price of Takeda Pharmaceutical (TAK)?

Takeda Pharmaceutical (TAK) last closed at $21.77.

What is the market cap of Takeda Pharmaceutical (TAK)?

The market cap of Takeda Pharmaceutical (TAK) is approximately $69.6B.